PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the dosing of the first patient in its Phase 1 ...

The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors.

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

Merus leads biotech with its innovative antibody platforms, strong financials, and promising petosemtamab targeting cancer.

Context Therapeutics (CNTX) announced that the first patient has been dosed in the Phase 1 clinical trial of CT-95, a mesothelin x CD3 T cell ...

Researchers from Sanofi SA reported the preclinical characterization of SAR-446159 (ABL-301), a bispecific antibody construct comprising an antibody targeting α-synuclein fused to an engineered ...

Global Bispecific Trispecific Antibodies Market Size Will Surpass US$ 50 Billion By 2030 Says Kuick ResearchDelhi, April 04, ...

On the commercial front, Akeso's adjustments in drug pricing and optimization of its commercial systems led to new drug sales revenue surpassing RMB 2 billion in 2024, a 25% year-on-year increase. The ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

Tecvvayli, Talvey, and Elrexfio demonstrate significant response rates and extended progression-free survival in heavily pretreated patients. Each bispecific antibody has a unique side effect profile, ...